2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2740

High Efficacy Of Toll-Like Receptor 4 Targeting In Murine and Humanized Models Of Rheumatoid Arthritis In Comparison With IL-1 and TNF Inhibitors
Abstract Number: 2485

High Incidence Of Disease Recurrence After Discontinuation Of Disease Modifying Anti-Rheumatic Drug Treatment In Patients With Psoriatic Arthritis In Remission
Abstract Number: 447

High Levels Of Memory B CELLS ARE Associated With Response To A First ANTI-TNF Drug In Patients With Rheumatoid Arthritis
Abstract Number: 458

High Levels Of Natural Killer CELLS ARE Associated With Response To Tocilizumab In Patients With Severe Rheumatoid Arthritis
Abstract Number: 1184

High Mobility Group Box 1 Plays a Role In Gouty Arthritis
Abstract Number: 2454

High Prevalence Of Left Ventricular Diastolic Dysfunction In Patients With Ankylosing Spondylitis
Abstract Number: 1683

High Prevalence Of Metabolic Syndrome In Takayasu Arteritis: An Increased Cardiovascular Risk and Lower Adiponectin Serum Levels
Abstract Number: 414

High Prevalence Of Obesity Among Early and Established Rheumatoid Arthritis
Abstract Number: 1599

High Proportion Of Intrathecal Ro52 SSA Antibodies In Neuropsychiatric Lupus Patients – Relations To Neuropsychiatric Manifestations
Abstract Number: 1349

High Rate Of Improvement In Serum Matrix Metalloproteinase-3 Levels At 4 Weeks Predict Remission At 52 Weeks In RA Patients With Adalimumab Therapy
Abstract Number: 1719

High Reliability Was Found for Ultrasound Scoring of Osteophytes in Patients With Hand Osteoarthritis Using An Atlas As Reference; An Omeract Initiative
Abstract Number: 1486

High Resolution HLA Analysis In Primary and Secondary Sjögren’s Syndrome
Abstract Number: 1407

High Serum Cholesterol Predicts Rheumatoid Arthritis In Women
Abstract Number: 913

High Throughput Epitope Mapping Of Autoantibodies In BXD2 Mice Reveals The Generation Of Autoantibodies Against Citrullinated Antigens At The Predicted Major Immunogenic Sites
Abstract Number: 2197

High Titer IgG Anti-Cyclic Citrullinated Peptide Antibodies Are Associated With Joint Destruction In Juvenile Idiopathic Arthritis Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].